PMID- 27326000
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160621
LR  - 20201001
IS  - 1759-1104 (Print)
IS  - 1759-1104 (Electronic)
IS  - 1759-1104 (Linking)
VI  - 3
IP  - 1
DP  - 2011
TI  - Comparison of efficacy and adverse effect profile of high dose versus standard 
      dose atorvastatin in acute ST elevation myocardial infarction patients.
PG  - 82-6
LID - 10.1136/ha.2010.003632 [doi]
AB  - OBJECTIVE: To compare the efficacy and adverse effects of high and standard dose 
      atorvastatin in ST elevation myocardial infarction (STEMI) patients. DESIGN: A 
      prospective, single-centre, randomised, double blind study. SETTING: A tertiary 
      care centre in Kerala, India, from January to June 2009. PATIENTS: 121 
      consecutive acute STEMI patients eligible for thrombolytic therapy. 
      INTERVENTIONS: Pharmacological thrombolysis and atorvastatin therapy. MAIN 
      OUTCOME MEASURES: Primary end points were mean change in low density lipoprotein 
      and total cholesterol, serum glutamic pyruvic transaminase (SGPT), creatine 
      phosphokinase (CPK) at 3 months of high dose (80 mg) and standard dose (20 mg) of 
      atorvastatin. RESULTS: There was no significant difference in the mean 
      cholesterol levels at 3 months of therapy (mean reduction in total cholesterol 
      and low density lipoprotein cholesterol were 48 mg%, 49 mg% in the 20 mg group 
      compared with 54 mg% and 53 mg%, respectively, in the 80 mg group; p 0.39 and 
      0.4). There was a significant increase in SGPT at 1 week in the 80 mg group and 
      atorvastatin was stopped in a significantly higher number of patients due to the 
      increase in SGPT and CPK at 1 week in the high dose group (12% and 7% of 
      patients; (p=0.04 and p=0.06, respectively). CONCLUSION: In acute STEMI patients 
      treated with pharmacological thrombolysis, standard dose atorvastatin is equally 
      effective as high dose atorvastatin in terms of reduction in cholesterol, with 
      higher and earlier incidence of asymptomatic SGPT and CPK elevation in the high 
      dose group.
FAU - Sebastian, Gailin B
AU  - Sebastian GB
AD  - Department of Cardiology, Kottayam Medical College, Kottayam, Kerala, India.
FAU - Anoop, T M
AU  - Anoop TM
AD  - Department of Medicine, Kottayam Medical College, Kottayam, Kerala, India.
FAU - Thomas, Joby K
AU  - Thomas JK
AD  - Department of Cardiology, Kottayam Medical College, Kottayam, Kerala, India.
FAU - George, Raju
AU  - George R
AD  - Department of Cardiology, Kottayam Medical College, Kottayam, Kerala, India.
LA  - eng
PT  - Journal Article
DEP - 20110101
PL  - England
TA  - Heart Asia
JT  - Heart Asia
JID - 101542742
PMC - PMC4898558
OTO - NOTNLM
OT  - Myocardial infarction
OT  - acute myocardial infarction
OT  - atorvastatin
COIS- Competing interests: None.
EDAT- 2011/01/01 00:00
MHDA- 2011/01/01 00:01
PMCR- 2011/01/01
CRDT- 2016/06/22 06:00
PHST- 2011/07/06 00:00 [accepted]
PHST- 2016/06/22 06:00 [entrez]
PHST- 2011/01/01 00:00 [pubmed]
PHST- 2011/01/01 00:01 [medline]
PHST- 2011/01/01 00:00 [pmc-release]
AID - heartasia-2010-003632 [pii]
AID - 10.1136/ha.2010.003632 [doi]
PST - epublish
SO  - Heart Asia. 2011 Jan 1;3(1):82-6. doi: 10.1136/ha.2010.003632. eCollection 2011.